54276-24-3

Usage

Uses

Used in Erectile Dysfunction Treatment:
15(S)-FLUPROSTENOL is used as a therapeutic agent for erectile dysfunction, helping to improve blood flow to the penile tissues, thereby facilitating erections.
Used in Peripheral Vascular Disease Treatment:
In the treatment of peripheral vascular disease, 15(S)-FLUPROSTENOL is utilized as a vasodilator to enhance blood circulation in the extremities, alleviating symptoms associated with poor blood flow.
Used in Ophthalmology:
15(S)-FLUPROSTENOL is used as a potential treatment for ocular hypertension and glaucoma, where its vasodilatory effects may help to reduce intraocular pressure.
Used in Platelet Aggregation Prevention:
15(S)-FLUPROSTENOL is used as an antiplatelet agent to prevent platelet aggregation, which can be beneficial in managing conditions that involve an increased risk of blood clot formation.
Used in Medical and Research Settings:
Due to its potent vasodilatory properties, 15(S)-FLUPROSTENOL is used in various medical and research settings to study and treat conditions that can benefit from improved blood flow and vascular health.

Relevant academic research and scientific papers

PROCESS FOR PREPARATION OF PROSTAGLANDIN F2 ALPHA ANALOGUES

A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.

PROCESS FOR PREPARATION OF PROSTAGLANDIN F2α ANALOGUES

A convergent synthesis of the prostaglandin F2α analogues, travoprost and bimatoprost, was developed employing Julia-Lythgoe olefination of the structurally advanced phenylsulfone with an enantiomerically pure aldehyde ω-chain synthon. The novel convergent strategy allows the synthesis of a whole series of prostaglandin analogues of high purity from a common and structurally advanced prostaglandin intermediate.

A novel convergent synthesis of the potent antiglaucoma agent travoprost

The 16-(3-trifluoromethyl)phenoxy PGF2α analogue travoprost (8a) has potent topical ocular activity. A novel convergent synthesis of 13,14-en-15-ol PGF2α analogues was developed employing Julia-Lythgoe olefination of the structurally advanced prostaglandin phenylsulfone (5Z)-(+)-15 with a new enantiomerically pure aldehyde ω-chain synthon (S)-(-)-16a. Subsequent hydrolysis of protecting groups and final esterification of fluprostenol (7a) yielded travoprost (8a). The main advantages are the preparation of high purity travoprost (8a) and the application of comparatively cheap reagents. The novel convergent strategy allows the synthesis of a whole series of 13,14-en-15-ol PGF2α analogues from a common and structurally advanced prostaglandin intermediate 15. The preparation and identification of two synthetic impurities, 15-epi isomer (8b) of travoprost and a new prostaglandin related ester (5Z)-(+)-18, are also described.

Synthesis of (±) travoprost and its analogs

A new synthetic approach for the antiglaucoma agent, travoprost (1) has been developed in four steps from key intermediate (2). Key transformations include Horner-Wadsworth-Emmons reaction and separation of diastereomers to obtain (±) travoprost (1) and its analogs.